Page last updated: 2024-11-12

cetilistat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cetilistat: lipase inhibitor in randomized, placebo-controlled study of weight reduction in obese patients (3/2007) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9952916
CHEMBL ID2103825
CHEBI ID134721
SCHEMBL ID367612
MeSH IDM0510243

Synonyms (51)

Synonym
AC-219
citilistat
cetilistat [inn]
CHEBI:134721
atl-962
cametor
cetilistat
cetilistat (jan/usan/inn)
D09208
oblean (tn)
282526-98-1
FT-0657021
4h-3,1-benzoxazin-4-one, 2-(hexadecyloxy)-6-methyl-
2-(hexadecyloxy)-6-methyl-4h-3,1-benzoxazin-4-one
lc5g1jua39 ,
atl 962
unii-lc5g1jua39
cetilistat [usan:inn:ban:jan]
2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one
A819389
AKOS015915375
CHEMBL2103825
S4930
MVCQKIKWYUURMU-UHFFFAOYSA-N
2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
KS-1251
cetilistat [usan]
cetilistat [mi]
cetilistat [jan]
cetilistat [who-dd]
SCHEMBL367612
oblean
C2745
DTXSID90182506
HY-14471
EX-A983
CS-5623
2-(hexadecyloxy)-6-methyl-4h-benzo[d][1,3]oxazin-4-one
BCP07371
Q3010545
F16711
mfcd09839697
atl962
DB06586
AMY25231
SB17399
HMS3873M13
CCG-268665
NCGC00408859-01
gtpl11433
BC166233

Research Excerpts

Overview

Cetilistat (CET) is a pancreatic lipase inhibitor approved for management of obesity after the serious adverse effects exhibited by its analogue orlistat. It is a novel, orally active, gastrointestinal and pancreaticlipase inhibitor.

ExcerptReferenceRelevance
"Cetilistat (CET) is a pancreatic lipase inhibitor approved for management of obesity after the serious adverse effects exhibited by its analogue orlistat. "( In vivo metabolic investigation of cetilistat in normal versus pseudo-germ-free rats using UPLC-QTOFMS/MS and in silico toxicological evaluation of its metabolites.
Mukesh, S; Sangamwar, AT; Talluri, MVNK; Tiwari, SS, 2020
)
2.28
"Cetilistat is a novel, orally active, gastrointestinal and pancreatic lipase inhibitor."( Cetilistat for the treatment of obesity.
Gras, J, 2013
)
2.55
"Cetilistat is a novel inhibitor of pancreatic lipase. "( Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.
Ashina, S; Kato, K; Kato, T; Ogino, H; Yamada, Y, 2008
)
3.23

Treatment

Treatment with cetilistat 80 or 120 mg t.i.d. significantly reduced body weight and improved glycemic control relative to placebo in obese diabetic patients. Treatment was well tolerated.

ExcerptReferenceRelevance
"Cetilistat treatment was well tolerated."( Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Bryson, A; Hickling, R; Kopelman, P; Rissanen, A; Rossner, S; Toubro, S; Valensi, P, 2007
)
2.5
"Treatment with cetilistat 80 or 120 mg t.i.d., or with orlistat 120 mg t.i.d., significantly reduced body weight and improved glycemic control relative to placebo in obese diabetic patients."( Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010
)
0.95
"Treatment with cetilistat reduced mean body weight to similar extents at all doses, which were statistically significant compared with placebo (60 mg t.i.d. "( Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Bryson, A; Hickling, R; Kopelman, P; Rissanen, A; Rossner, S; Toubro, S; Valensi, P, 2007
)
2.14

Toxicity

ExcerptReferenceRelevance
" However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin."( Tolerability and safety of the new anti-obesity medications.
Aldhoon-Hainerová, I; Hainer, V, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoxazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's8 (57.14)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.35 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index80.20 (26.88)
Search Engine Supply Index3.54 (0.95)

This Compound (35.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (21.43%)5.53%
Reviews6 (42.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (35.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers [NCT00148382]Phase 180 participants Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]